loading
Schlusskurs vom Vortag:
$1.16
Offen:
$1.16
24-Stunden-Volumen:
41,303
Relative Volume:
0.17
Marktkapitalisierung:
$71.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.0313
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
-8.71%
1M Leistung:
+12.76%
6M Leistung:
-33.13%
1J Leistung:
-51.77%
1-Tages-Spanne:
Value
$1.13
$1.165
1-Wochen-Bereich:
Value
$1.12
$1.2629
52-Wochen-Spanne:
Value
$0.8551
$3.60

Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile

Name
Firmenname
Acumen Pharmaceuticals Inc
Name
Telefon
925-368-8508
Name
Adresse
427 PARK ST., CHARLOTTESVILLE
Name
Mitarbeiter
52
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
ABOS's Discussions on Twitter

Vergleichen Sie ABOS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABOS
Acumen Pharmaceuticals Inc
1.155 71.48M 0 -64.86M -55.66M -1.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.17 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
544.84 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.89 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
558.32 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.63 28.51B 3.81B -644.79M -669.77M -6.24

Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-26 Eingeleitet Citigroup Buy
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-07-20 Fortgesetzt BofA Securities Buy
2023-05-18 Eingeleitet Cantor Fitzgerald Overweight
2022-07-15 Eingeleitet BTIG Research Buy
2022-06-30 Eingeleitet H.C. Wainwright Buy
2022-01-21 Hochstufung BofA Securities Neutral → Buy
2021-07-26 Eingeleitet BofA Securities Neutral
2021-07-26 Eingeleitet Credit Suisse Outperform
2021-07-26 Eingeleitet Stifel Buy
2021-07-26 Eingeleitet UBS Buy
Alle ansehen

Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten

pulisher
Jun 18, 2025

Acumen Pharmaceuticals (NASDAQ:ABOS) Now Covered by Citigroup - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Citi initiates Acumen Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Coverage on Acumen Pharmaceuticals (ABOS) wi - GuruFocus

Jun 17, 2025
pulisher
Jun 15, 2025

Bank of America Corp DE Boosts Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Jun 15, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Estimates ABOS FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews

Jun 10, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Lowers Holdings in Vicor Co. (NASDAQ:VICR) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Sells 8,239 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Jun 10, 2025
pulisher
Jun 05, 2025

Acumen Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 03, 2025

Deutsche Bank AG Increases Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Millennium Management LLC Acquires New Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Cryptocurrency Stocks To Follow Today – May 30th - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Halozyme to Participate at Upcoming Investor Conferences - The Malaysian Reserve

May 29, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow

May 28, 2025
pulisher
May 19, 2025

FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald - Defense World

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Purchases 41,460 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 18, 2025
pulisher
May 17, 2025

Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development - MSN

May 17, 2025
pulisher
May 16, 2025

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Ovid Therapeutics (OVID) - The Globe and Mail

May 16, 2025
pulisher
May 15, 2025

Acumen Pharmaceuticals’ Earnings Call Highlights Progress in Alzheimer’s Treatment - TipRanks

May 15, 2025
pulisher
May 15, 2025

Tower Research Capital LLC TRC Purchases 16,714 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 15, 2025
pulisher
May 14, 2025

Transcript : Acumen Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Barclays PLC Raises Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 14, 2025
pulisher
May 14, 2025

Barclays PLC Raises Stock Holdings in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World

May 14, 2025
pulisher
May 14, 2025

Acumen Pharmaceuticals Q1 2025 Financial Update - TipRanks

May 14, 2025
pulisher
May 14, 2025

ABOS Reports Decline in Cash Reserves to Support Operations | AB - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Earnings call transcript: Acumen Pharmaceuticals Q1 2025 financial results and stock gains - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Acumen (ABOS) Advances in Alzheimer's Treatment Study | ABOS Sto - GuruFocus

May 13, 2025
pulisher
May 13, 2025

ACUMEN PHARMACEUTICALS Earnings Results: $ABOS Reports Quarterly Earnings - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 11, 2025

Acumen Pharmaceuticals (ABOS) to Release Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 09, 2025

Acumen Pharmaceuticals Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

May 09, 2025
pulisher
May 08, 2025

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference - The Manila Times

May 08, 2025
pulisher
May 06, 2025

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Upcoming Earnings: Alzheimer's Drug Developer Acumen Pharmaceuticals Reports Q1 Results May 13 - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - The Malaysian Reserve

May 05, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Cuts Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 05, 2025
pulisher
Apr 28, 2025

Halozyme to Report First Quarter 2025 Financial and Operating Results - Yahoo Finance

Apr 28, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Apr 26, 2025
pulisher
Apr 17, 2025

ABOS stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

ABOS stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

Apr 17, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Finansavisen

Apr 07, 2025
pulisher
Apr 03, 2025

Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) & Precision BioSciences (NASDAQ:DTIL) - The AM Reporter

Apr 03, 2025
pulisher
Apr 02, 2025

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter

Mar 31, 2025

Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Zuga Matt
CFO & Chief Business Officer
Jan 21 '25
Sale
1.60
4,364
6,986
260,646
OConnell Daniel Joseph
Chief Executive Officer
Jan 21 '25
Sale
1.59
12,619
20,102
667,488
Meisner Derek M
Chief Legal Officer & Corp Sec
Jan 21 '25
Sale
1.59
3,418
5,435
161,127
Barton Russell
Chief Operating Officer
Jan 21 '25
Sale
1.61
2,914
4,692
136,117
Siemers Eric
Chief Medical Officer
Jan 21 '25
Sale
1.59
3,219
5,118
170,298
$20.95
price up icon 1.46%
$36.04
price up icon 0.14%
$21.25
price down icon 0.39%
$98.93
price down icon 1.52%
$108.80
price up icon 2.21%
biotechnology ONC
$244.22
price up icon 0.68%
Kapitalisierung:     |  Volumen (24h):